What's Needed Now

Editor's Note: This Opinion is adapted from remarks prepared for a hearing of the U.S. Senate Health, Education, Labor and Pensions Committee, chaired at the time by Sen. James Jeffords, then a Republican, now an Independent, of Vermont. I had the privilege to speak to a recent Senate committee panel about the unprecedented research opportunities in the medical and health sciences. These opportunities are unprecedented because of the advances in cell and molecular biology, in information and c

Written bySamuel Silverstein
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The opportunities of which I speak are the result of past public and private investments in the physical and biological sciences by many individuals and many nations. In the last 50 years, thanks to the work of many of the members of this committee, and of their colleagues in the House of Representatives, as well as former leaders like Senator Mark Hatfield, the United States has led the world in the generosity of its commitments to medical and health research.

As Americans, we should be proud of these commitments. Twenty thousand children won't get meningitis this year because of the availability of a vaccine against Hemophilus influenza b, and 450,000 adults who would have died in 1970 will not die this year because of better methods for preventing, diagnosing, and treating cardiovascular diseases. New drugs and treatments provide hope for advances on other fronts.

We still have a long way ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies